

# Samia Mora

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/614047/publications.pdf>

Version: 2024-02-01

211  
papers

28,149  
citations

13865

67  
h-index

5679

162  
g-index

216  
all docs

216  
docs citations

216  
times ranked

31762  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia—a randomized controlled feeding trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 154-162.	4.7	55
2	Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 525-537.	3.6	4
3	Mediterranean Diet Social Network Impact along 11 Years in the Major US Media Outlets: Thematic and Quantitative Analysis Using Twitter. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 784.	2.6	7
4	Association of Modifiable Lifestyle Factors with Plasma Branched-Chain Amino Acid Metabolites in Women. <i>Journal of Nutrition</i> , 2022, 152, 1515-1524.	2.9	6
5	Managing Atherosclerotic Cardiovascular Risk in Young Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 819-836.	2.8	72
6	Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1501-1510.	4.7	17
7	Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1490-1500.	4.7	71
8	Red blood cell fatty acid patterns from 7 countries: Focus on the Omega-3 index. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2022, 179, 102418.	2.2	21
9	Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization. <i>JACC: Heart Failure</i> , 2022, 10, 227-234.	4.1	8
10	Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>JAMA Internal Medicine</i> , 2022, 182, 587.	5.1	4
11	The Curious Case of Synergy between Lipoprotein (a), Coronary Calcification, and Cardiovascular Disease Risk. <i>Clinical Chemistry</i> , 2022, 68, 1235-1237.	3.2	1
12	Fasting status and metabolic health in relation to plasma branched chain amino acid concentrations in women. <i>Metabolism: Clinical and Experimental</i> , 2021, 117, 154391.	3.4	8
13	Nonfasting Lipids for All Patients?. <i>Clinical Chemistry</i> , 2021, 67, 41-45.	3.2	7
14	Association of obesity indices with in-hospital and 1-year mortality following acute coronary syndrome. <i>International Journal of Obesity</i> , 2021, 45, 358-368.	3.4	8
15	Effects of Vitamin D3 Supplementation on Body Composition in the VITamin D and Omega-3 Trial (VITAL). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1377-1388.	3.6	18
16	Marine Omega-3 Fatty Acids and Cardiovascular Disease Prevention: Seeking Clearer Water. <i>Mayo Clinic Proceedings</i> , 2021, 96, 277-279.	3.0	7
17	Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1061.	7.4	73
18	SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 4945.	3.3	19

#	ARTICLE	IF	CITATIONS
19	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiology, 2021, 6, 437.	6.1	82
20	Abstract 019: Modifiable Lifestyle Factors And Plasma Branched Chain Amino Acids: An Analysis Of N=19,472 US Women. Circulation, 2021, 143, .	1.6	1
21	Misperceptions and management of risk: Ongoing challenges in women's cardiovascular health. Atherosclerosis, 2021, 324, 109-111.	0.8	4
22	Branched-Chain Amino Acids and Risk of Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkab059.	2.9	12
23	Risk Factors for Premature Myocardial Infarction: A Systematic Review and Meta-analysis of 77 Studies. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 783-794.	2.4	18
24	Sugar-Sweetened Beverage Consumption May Modify Associations Between Genetic Variants in the CHREBP (Carbohydrate Responsive Element Binding Protein) Locus and HDL-C (High-Density Lipoprotein) Tj ETQq0,0,0 rgBT /Overlock 1 e003288.	3.6	8
25	Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. Circulation Genomic and Precision Medicine, 2021, 14, e003330.	3.6	19
26	Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study. Thyroid, 2021, 31, 1305-1315.	4.5	13
27	A Still-Ignored Cardiovascular Risk Factorâ€”A History of Preeclampsiaâ€”Reply. JAMA Cardiology, 2021, 6, 1098.	6.1	0
28	Lifelong low Lp(a) levels: genetics give a green light?. European Heart Journal, 2021, 42, 1157-1159.	2.2	7
29	Assessing the dyslipidemias: to fast or not to fast?. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 97-103.	2.3	1
30	Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions. Neurology, 2021, 97, e2223-e2235.	1.1	7
31	1102â€¦Fish oil supplementation and pro-inflammatory and pro-resolving lipid mediators in patients with and without systemic lupus erythematosus. , 2021, , .		1
32	Exercise-Induced Ventricular Ectopy andÂ Cardiovascular Mortality in Asymptomatic Individuals. Journal of the American College of Cardiology, 2021, 78, 2267-2277.	2.8	20
33	Glycosylation and Cardiovascular Diseases. Advances in Experimental Medicine and Biology, 2021, 1325, 307-319.	1.6	9
34	Abstract 11848: Biomarkers of Glucose-Insulin Homeostasis, Randomized Treatment With Omega-3 and Vitamin D Supplementation, and Incident Type 2 Diabetes: Prospective Analysis From the Vitamin D and Omega-3 Trial (VITAL). Circulation, 2021, 144, .	1.6	0
35	The association of cardiovascular mortality with a first-degree family member history of different cardiovascular diseases. Journal of Geriatric Cardiology, 2021, 18, 816-824.	0.2	1
36	Abstract 12860: Effects of Marine Omega-3 and Vitamin D Supplementation on Circulating Biomarkers of Glucose-Insulin Homeostasis and Incident Cardiovascular Disease in the Vitamin D and Omega-3 Trial (VITAL). Circulation, 2021, 144, .	1.6	0

#	ARTICLE	IF	CITATIONS
37	Premature Myocardial Infarction in the Middle East and North Africa: Rationale for the Gulf PREVENT Study. <i>Angiology</i> , 2020, 71, 17-26.	1.8	14
38	Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization. <i>Circulation</i> , 2020, 141, 784-786.	1.6	41
39	Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and Omega-3 Trial (VITAL). <i>Journal of Bone and Mineral Research</i> , 2020, 35, 883-893.	2.8	69
40	Lp(a)'s Odyssey. <i>Journal of the American College of Cardiology</i> , 2020, 75, 145-147.	2.8	3
41	Hypothyroidism and Kidney Function: A Mendelian Randomization Study. <i>Thyroid</i> , 2020, 30, 365-379.	4.5	27
42	Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence. <i>Circulation Research</i> , 2020, 126, 112-128.	4.5	45
43	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 496-517.	2.3	119
44	Circulating branched-chain amino acids and long-term risk of obesity-related cancers in women. <i>Scientific Reports</i> , 2020, 10, 16534.	3.3	22
45	Probabilistic identification of saccharide moieties in biomolecules and their protein complexes. <i>Scientific Data</i> , 2020, 7, 210.	5.3	4
46	One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL). <i>Metabolites</i> , 2020, 10, 431.	2.9	13
47	Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016507.	3.7	21
48	Concordance of Cardiovascular Risk Factors and Behaviors in a Multiethnic US Nationwide Cohort of Married Couples and Domestic Partners. <i>JAMA Network Open</i> , 2020, 3, e2022119.	5.9	26
49	Effects of a Low-Carbohydrate Diet on Cardiometabolic Risk Factors During Weight-Loss Maintenance: A Randomized Controlled Feeding Trial. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa049_018.	0.3	1
50	Habitual Fish Consumption, n-3 Fatty Acids, and Nuclear Magnetic Resonance Lipoprotein Subfractions in Women. <i>Journal of the American Heart Association</i> , 2020, 9, e014963.	3.7	14
51	Quantum approximate Bayesian computation for NMR model inference. <i>Nature Machine Intelligence</i> , 2020, 2, 396-402.	16.0	12
52	Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and Omega-3 Trial. <i>Journal of Clinical Lipidology</i> , 2020, 14, 241-251.	1.5	17
53	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , 2020, 294, 46-61.	0.8	137
54	Association of the Mediterranean Diet With Onset of Diabetes in the Women's Health Study. <i>JAMA Network Open</i> , 2020, 3, e2025466.	5.9	28

#	ARTICLE	IF	CITATIONS
55	Abstract 13479: Association of Plasma Branched Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. <i>Circulation</i> , 2020, 142, .	1.6	1
56	Abstract 16278: Discordant Lipid Phenotype and Other Determinants of Statin Response in the Pravastatin Inflammation/crp Evaluation (PRINCE) Trial. <i>Circulation</i> , 2020, 142, .	1.6	0
57	Cholesterol Insights and Controversies From the UK Biobank Study. <i>Circulation</i> , 2019, 140, 553-555.	1.6	8
58	Statistical Workflow for Feature Selection in Human Metabolomics Data. <i>Metabolites</i> , 2019, 9, 143.	2.9	55
59	A little more time around the track may go a long way: Implications of increasing moderate to vigorous physical activity in pre-adolescents. <i>Atherosclerosis</i> , 2019, 288, 160-162.	0.8	0
60	Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL. <i>Clinical Chemistry</i> , 2019, 65, 1487-1492.	3.2	3
61	Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. <i>Clinical Chemistry</i> , 2019, 65, 1508-1521.	3.2	23
62	Serum 25-hydroxyvitamin D in the VITamin D and Omega-3 Trial (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment. <i>Contemporary Clinical Trials</i> , 2019, 87, 105854.	1.8	24
63	Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 144.	6.1	64
64	The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis. <i>Atherosclerosis</i> , 2019, 282, 91-99.	0.8	23
65	Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm. <i>JAMA Internal Medicine</i> , 2019, 179, 898.	5.1	46
66	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2019, 17, 538-540.	1.7	23
67	Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment. <i>Thyroid</i> , 2019, 29, 760-777.	4.5	61
68	Thyroid and Cardiovascular Disease. <i>Circulation</i> , 2019, 139, 2892-2909.	1.6	51
69	Group IIA Secretory Phospholipase A <sub>2</sub> , Vascular Inflammation, and Incident Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1182-1190.	2.4	25
70	GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis. <i>Angiology</i> , 2019, 70, 737-746.	1.8	17
71	Risk factors associated with premature myocardial infarction: a systematic review protocol. <i>BMJ Open</i> , 2019, 9, e023647.	1.9	11
72	GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. <i>Aids</i> , 2019, 33, 547-557.	2.2	27

#	ARTICLE	IF	CITATIONS
73	Association of High-Density Lipoprotein Particles and High-Density Lipoprotein Apolipoprotein C-III Content With Cardiovascular Disease Risk According to Kidney Function: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of the American Heart Association</i> , 2019, 8, e013713.	3.7	9
74	Fibroblast growth factor-21 levels in metabolic syndrome: Another instrument in a widening tool belt?. <i>Atherosclerosis</i> , 2019, 281, 143-144.	0.8	2
75	Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019, 380, 33-44.	27.0	1,141
76	Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 23-32.	27.0	684
77	Directed Non-targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids and Related Oxylipins. <i>Cell Chemical Biology</i> , 2019, 26, 433-442.e4.	5.2	64
78	Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women's Genome Health Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 97-106.	2.4	10
79	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. <i>Current Vascular Pharmacology</i> , 2019, 17, 515-537.	1.7	19
80	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019, 17, 498-514.	1.7	38
81	Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. <i>Current Atherosclerosis Reports</i> , 2018, 20, 15.	4.8	5
82	The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering. <i>Circulation</i> , 2018, 137, 20-23.	1.6	12
83	Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study. <i>American Journal of Epidemiology</i> , 2018, 187, 705-716.	3.4	40
84	Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study. <i>Clinical Chemistry</i> , 2018, 64, 231-241.	3.2	10
85	Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi-Ethnic Study of Atherosclerosis. <i>Clinical Cardiology</i> , 2018, 41, 1439-1445.	1.8	23
86	Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet. <i>JAMA Network Open</i> , 2018, 1, e185708.	5.9	65
87	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018, 392, 1311-1320.	13.7	355
88	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): An Overlooked Form of Hypoglycemia in Clinical Practice. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-6.	1.5	6
89	Altered branched chain amino acid metabolism. <i>Current Opinion in Cardiology</i> , 2018, 33, 558-564.	1.8	34
90	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	3.2	189

#	ARTICLE	IF	CITATIONS
91	Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	3
92	Dietary Intakes and Circulating Concentrations of Branched-Chain Amino Acids in Relation to Incident Type 2 Diabetes Risk Among High-Risk Women with a History of Gestational Diabetes Mellitus. <i>Clinical Chemistry</i> , 2018, 64, 1203-1210.	3.2	64
93	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. <i>JAMA Internal Medicine</i> , 2018, 178, 1231.	5.1	58
94	Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002157.	3.6	145
95	Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. <i>Journal of the American College of Cardiology</i> , 2018, 72, 287-296.	2.8	73
96	Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence. <i>Circulation</i> , 2018, 138, 2330-2341.	1.6	98
97	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. <i>Clinical Chemistry</i> , 2017, 63, 870-879.	3.2	74
98	Predicting Asthma Exacerbations from a Drop of Blood. <i>Clinical Chemistry</i> , 2017, 63, 799-801.	3.2	1
99	Risk and Benefit Information and Use of Aspirin—Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 291.	5.1	0
100	Effects of statins on the immunoglobulin G glycome. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 1152-1158.	2.4	20
101	Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 976-982.	2.4	79
102	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. <i>Circulation</i> , 2017, 135, 2494-2504.	1.6	180
103	Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women. <i>Journal of the Endocrine Society</i> , 2017, 1, 113-123.	0.2	16
104	Genetic associations with lipoprotein subfraction measures differ by ethnicity in the multi-ethnic study of atherosclerosis (MESA). <i>Human Genetics</i> , 2017, 136, 715-726.	3.8	12
105	Partitioning the Genetic Architecture of Plasma Lipoprotein(a) and Kringle IV Type 2 Repeats: Implications for Therapeutic Lowering. <i>Clinical Chemistry</i> , 2017, 63, 1792-1794.	3.2	0
106	Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	98
107	Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1257-1267.e2.	1.5	40
108	Association of High-Density Lipoprotein Cholesterol Versus Apolipoprotein A With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer—Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	13



#	ARTICLE	IF	CITATIONS
109	Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Veryâ€Lowâ€Density Lipoproteins. Journal of the American Heart Association, 2017, 6, .	3.7	61
110	Is it time to abandon fasting for routine lipid testing?. Cleveland Clinic Journal of Medicine, 2017, 84, 919-922.	1.3	6
111	Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Diseaseâ€”Reply. JAMA - Journal of the American Medical Association, 2016, 316, 2276.	7.4	0
112	Circulating Nâ€Linked Glycoprotein Sideâ€Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. Journal of the American Heart Association, 2016, 5, .	3.7	44
113	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpointsâ€”A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry, 2016, 62, 930-946.	3.2	145
114	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 136.	6.1	53
115	Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). American Journal of Cardiology, 2016, 117, 1921-1927.	1.6	43
116	Lipid biomarkers and long-term risk of cancer in the Womenâ€™s Health Study. American Journal of Clinical Nutrition, 2016, 103, 1397-1407.	4.7	117
117	Nonfasting for Routine Lipid Testing. JAMA Internal Medicine, 2016, 176, 1005.	5.1	38
118	Glycosylation Signatures of Inflammation Identify Cardiovascular Risk. Circulation Research, 2016, 119, 1154-1156.	4.5	17
119	Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2016, 316, 709.	7.4	33
120	Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease. JAMA Internal Medicine, 2016, 176, 1195.	5.1	58
121	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-pointsâ€”a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 2016, 37, 1944-1958.	2.2	542
122	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. Clinical Chemistry, 2016, 62, 428-435.	3.2	22
123	Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circulation Research, 2016, 118, 1106-1115.	4.5	97
124	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science, 2016, 351, 1166-1171.	12.6	438
125	Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. European Heart Journal, 2016, 37, 1373-1379.	2.2	180
126	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. PLoS ONE, 2016, 11, e0165615.	2.5	31



#	ARTICLE	IF	CITATIONS
127	Re-assessing the role of non-fasting lipids; a change in perspective. <i>Annals of Translational Medicine</i> , 2016, 4, 431-431.	1.7	16
128	Fasting for Laboratory Tests Poses a High Risk of Hypoglycemia in Patients with Diabetes: A Pilot Prevalence Study in Clinical Practice. <i>International Journal of Clinical Medicine</i> , 2016, 07, 653-667.	0.2	5
129	Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1544-1550.	2.4	105
130	Lipoprotein Particles and Incident Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis. <i>Diabetes Care</i> , 2015, 38, 628-636.	8.6	120
131	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. <i>Clinical Chemistry</i> , 2015, 61, 1156-1163.	3.2	53
132	Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)". <i>Circulation</i> , 2015, 131, e473.	1.6	1
133	Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo. <i>Circulation</i> , 2015, 132, 2220-2229.	1.6	101
134	Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 688-695.	5.1	6
135	A Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians. <i>PLoS ONE</i> , 2015, 10, e0120758.	2.5	323
136	High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 55-63.	2.2	56
137	Response to Letter Regarding Article, "Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Tj ETQq1 1 0.78431.4 rgBT / Overlock 10	1.4	10
138	Moving Beyond Mean Glycemia: 1,5-Anhydroglucitol and Microvascular Complications of Diabetes. <i>Clinical Chemistry</i> , 2014, 60, 1359-1361.	3.2	2
139	A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events. <i>Journal of the American Heart Association</i> , 2014, 3, e001221.	3.7	179
140	Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events. <i>Circulation</i> , 2014, 129, 553-561.	1.6	189
141	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 866-875.	1.8	18
142	Paradoxical Association of Lipoprotein Measures With Incident Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 612-619.	4.8	75
143	The Guidelines Battle on Starting Statins. <i>New England Journal of Medicine</i> , 2014, 370, 1652-1658.	27.0	19
144	Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL). <i>American Journal of Cardiology</i> , 2014, 113, 1378-1382.	1.6	27

#	ARTICLE	IF	CITATIONS
145	Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk. <i>Circulation</i> , 2014, 129, 635-642.	1.6	338
146	Response to Letter Regarding Article, "High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy". <i>Circulation</i> , 2014, 129, e481.	1.6	0
147	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2014, 64, 485-494.	2.8	512
148	Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30Âmg/dl) With Rosuvastatin 20Âmg Daily (from JUPITER). <i>American Journal of Cardiology</i> , 2014, 114, 1682-1689.	1.6	53
149	Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality. <i>Circulation</i> , 2014, 130, 546-553.	1.6	118
150	What's Different about Women's Health?. <i>Clinical Chemistry</i> , 2014, 60, 1-3.	3.2	8
151	Discovery and refinement of loci associated with lipid levels. <i>Nature Genetics</i> , 2013, 45, 1274-1283.	21.4	2,641
152	Common variants associated with plasma triglycerides and risk for coronary artery disease. <i>Nature Genetics</i> , 2013, 45, 1345-1352.	21.4	754
153	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. <i>Circulation</i> , 2013, 128, 1504-1512.	1.6	162
154	Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imaging. <i>European Heart Journal</i> , 2013, 34, 2074-2082.	2.2	6
155	Are There Sex Differences in Acute Coronary Syndrome Presentation?. <i>JAMA Internal Medicine</i> , 2013, 173, 1861.	5.1	6
156	High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy. <i>Circulation</i> , 2013, 128, 1189-1197.	1.6	203
157	A Comparison of the Theoretical Relationship between HDL Size and the Ratio of HDL Cholesterol to Apolipoprotein A-I with Experimental Results from the Women's Health Study. <i>Clinical Chemistry</i> , 2013, 59, 949-958.	3.2	48
158	Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels. <i>Evidence-Based Medicine</i> , 2012, 17, 133-134.	0.6	1
159	Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1302.	7.4	650
160	Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy. <i>Circulation</i> , 2012, 125, 1979-1987.	1.6	149
161	Fasting for Lipid Testing: Is It Worth the Trouble?. <i>Archives of Internal Medicine</i> , 2012, 172, 1710.	3.8	22
162	On-Treatment Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1521-1528.	2.8	90

#	ARTICLE	IF	CITATIONS
163	High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events. Journal of the American College of Cardiology, 2012, 60, 508-516.	2.8	325
164	Aspirin Therapy in Primary Prevention. Archives of Internal Medicine, 2012, 172, 217.	3.8	11
165	A National Interactive Web-Based Physical Activity Intervention in Women, Evaluation of the American Heart Association Choose to Move Program 2006-2007. American Journal of Cardiology, 2012, 109, 1754-1760.	1.6	21
166	Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. Journal of Clinical Lipidology, 2011, 5, 105-113.	1.5	311
167	Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels. Annals of Internal Medicine, 2011, 155, 742.	3.9	52
168	Lipoprotein Subclass Abnormalities and Incident Hypertension in Initially Healthy Women. Clinical Chemistry, 2011, 57, 1178-1187.	3.2	42
169	Lifestyle Interaction With Fat Mass and Obesity-Associated ( <i>FTO</i> ) Genotype and Risk of Obesity in Apparently Healthy U.S. Women. Diabetes Care, 2011, 34, 675-680.	8.6	84
170	Physical Activity Attenuates the Influence of <i>FTO</i> Variants on Obesity Risk: A Meta-Analysis of 218,166 Adults and 19,268 Children. PLoS Medicine, 2011, 8, e1001116.	8.4	446
171	Exercise Treadmill Stress Testing With and Without Imaging. , 2011, , 489-502.		1
172	Providing Patients With Global Cardiovascular Risk Information. Archives of Internal Medicine, 2010, 170, 227.	3.8	9
173	Lipoprotein(a) and Risk of Type 2 Diabetes. Clinical Chemistry, 2010, 56, 1252-1260.	3.2	165
174	Exercise Blood Pressure and Future Cardiovascular Death in Asymptomatic Individuals. Circulation, 2010, 121, 2109-2116.	1.6	130
175	Response to Letters Regarding Article, "Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women from Primary Prevention Trials". Circulation, 2010, 122, .	1.6	0
176	Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women. Diabetes, 2010, 59, 1153-1160.	0.6	157
177	Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia. Circulation, 2010, 121, 1069-1077.	1.6	287
178	The Fat-Mass and Obesity-Associated ( <i>FTO</i> ) gene, physical activity, and risk of incident cardiovascular events in white women. American Heart Journal, 2010, 160, 1163-1169.	2.7	51
179	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet, The, 2010, 376, 333-339.	13.7	221
180	The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines. Clinical Chemistry, 2009, 55, 219-228.	3.2	86

#	ARTICLE	IF	CITATIONS
181	Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use. Circulation, 2009, 119, 2396-2404.	1.6	77
182	Response to Letter Regarding Article, "Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events" Circulation, 2009, 119, .	1.6	4
183	AHA/ACCF 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. Circulation, 2009, 120, 1296-1336.	1.6	117
184	Comparison of LDL Cholesterol Concentrations by Friedewald Calculation and Direct Measurement in Relation to Cardiovascular Events in 27 331 Women. Clinical Chemistry, 2009, 55, 888-894.	3.2	153
185	Aspirin Therapy in Women. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 63-64.	2.2	5
186	Response to Letter Regarding Article, "Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women" Circulation, 2009, 120, .	1.6	1
187	Biphasic Pulmonary Regurgitation. Echocardiography, 2009, 26, 720-723.	0.9	2
188	Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women. Circulation, 2009, 119, 931-939.	1.6	427
189	ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. Journal of the American College of Cardiology, 2009, 54, 1364-1405.	2.8	80
190	Use of High-Sensitivity C-Reactive Protein for Risk Assessment. , 2009, , 158-166.		0
191	Forty-Three Loci Associated with Plasma Lipoprotein Size, Concentration, and Cholesterol Content in Genome-Wide Analysis. PLoS Genetics, 2009, 5, e1000730.	3.5	300
192	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 2008, 359, 2195-2207.	27.0	5,712
193	The use of high-sensitivity assays for C-reactive protein in clinical practice. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 621-635.	3.3	123
194	Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events. Circulation, 2008, 118, 993-1001.	1.6	366
195	Homocysteine, 5,10-Methylenetetrahydrofolate Reductase 677C>T Polymorphism, Nutrient Intake, and Incident Cardiovascular Disease in 24 968 Initially Healthy Women. Clinical Chemistry, 2007, 53, 845-851.	3.2	62
196	Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women. JAMA - Journal of the American Medical Association, 2007, 298, 309.	7.4	1,326
197	LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2007, 192, 211-217.	0.8	322
198	Physical Activity and Reduced Risk of Cardiovascular Events. Circulation, 2007, 116, 2110-2118.	1.6	799

#	ARTICLE	IF	CITATIONS
199	Blood pressure and risk of developing type 2 diabetes mellitus: The Women's Health Study. European Heart Journal, 2007, 28, 2937-2943.	2.2	153
200	Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease. Diabetes Research and Clinical Practice, 2006, 74, 267-273.	2.8	6
201	The Metabolic Syndrome in Women. Cardiology in Review, 2006, 14, 286-291.	1.4	96
202	Gender-Specific Prediction of Cardiac Disease. Cardiology in Review, 2006, 14, 281-285.	1.4	16
203	Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)â€”Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?. American Journal of Cardiology, 2006, 97, 33-41.	1.6	182
204	Association of Physical Activity and Body Mass Index With Novel and Traditional Cardiovascular Biomarkers in Women. JAMA - Journal of the American Medical Association, 2006, 295, 1412.	7.4	331
205	Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events. Circulation, 2006, 114, 381-387.	1.6	76
206	Interaction of Body Mass Index and Framingham Risk Score in Predicting Incident Coronary Disease in Families. Circulation, 2005, 111, 1871-1876.	1.6	77
207	Enhanced Risk Assessment in Asymptomatic Individuals With Exercise Testing and Framingham Risk Scores. Circulation, 2005, 112, 1566-1572.	1.6	90
208	Ability of Exercise Testing to Predict Cardiovascular and All-Cause Death in Asymptomatic Women. JAMA - Journal of the American Medical Association, 2003, 290, 1600-7.	7.4	472
209	Coronary artery disease in postmenopausal women. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 67-79.	0.9	6
210	Certain cardiac risk factors predict risk factor interventions and influence communication between physicians and patients. American Journal of Cardiology, 2000, 86, 783-785.	1.6	1
211	Mediterranean diet social network impact along 11 years in the major US media outlets: Thematic and Quantitative Analysis using Twitter. (Preprint). JMIR Public Health and Surveillance, 0, , .	2.6	0